FINWIRES · TerminalLIVE
FINWIRES

Rollins' Medium-Term Outlook Backed by Pricing, Recurring Revenue, Acquisitions, RBC Says

By

Rollins' (ROL) medium-term outlook, shared at its investor day, is backed by steady growth from pricing, recurring revenue, and acquisitions, RBC Capital Markets said in a note Thursday.

The company reaffirmed 2026 guidance of 7% to 8% organic revenue growth, 2% to 3% merger and acquisition contribution, and 25% to 30% adjusted incremental margins, while maintaining a medium-term outlook for above-market growth, double-digit earnings and free cash flow growth, 30% to 35% incremental earnings before interest, taxes, depreciation and amortization margins, and over 100% free cash flow conversion, the analyts said.

The company projects double-digit earnings growth to be supported by gross margin gains from consumer price index-plus pricing, lower technician turnover, procurement and fleet efficiencies, and selling, general and administrative expense reduction from back-office modernization and a shared services operating model, the analysts added.

The analysts said they model total revenue growth of about 9.7% year-over-year to $4.13 billion, including 7.1% organic growth, driven by Residential revenue of $1.84 billion, Commercial revenue of $1.37 billion, and Termite revenue of $875 million. They also estimate adjusted EBITDA of $946 million with a 22.9% margin, and adjusted earnings per share of $1.23 versus consensus of $1.24.

RBC has an outperform rating and a $67 price target on Rollins.

Price: $53.62, Change: $+0.20, Percent Change: +0.37%

Related Articles

Wire

Aardvark Therapeutics' Investigational New Drug Application for ARD-101 Put on Clinical Hold by FDA

Aardvark Therapeutics (AARD) said late Thursday the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101 to treat hyperphagia associated with Prader-Willi Syndrome.The hold applies to all ongoing clinical studies under the IND, the company said, adding that it is in discussions with the FDA for resolution of the clinical hold and to fix a path forward for the drug candidate.The company also plans to unblind clinical data from the HERO and OLE trials to assess the totality of efficacy and safety data, according to the company.The company said it had $91.2 million in cash and cash equivalents as of March 31, adequate to fund operations into mid-2027.

$AARD
Wire

Sky Harbour Q1 Loss Narrows, Revenue Rises; Shares Fall After Hours

Sky Harbour Group (SKYH) reported a Q1 loss late Thursday of $0.16 per diluted share, narrowing from a loss of $0.19 a year earlier.Analysts polled by FactSet expected a loss of $0.13.Revenue in the three months ended March 31 rose to $8.73 million from $5.59 million a year earlier.Analysts surveyed by FactSet expected $9.8 million.Sky Harbour shares fell 4.9% in after-hours trading.

$SKYH
Wire

KinderCare Learning Q1 Adjusted Earnings Fall, Revenue Rises; Shares Drop After Hours

KinderCare Learning (KLC) reported Q1 adjusted earnings late Thursday of $0.04 per diluted share, down from $0.23 a year earlier.Analysts surveyed by FactSet expected a loss of $0.01.Revenue in the three months ended April 4 rose to $672.5 million from $668.2 million a year earlier.Analysts surveyed by FactSet expected $669.1 million.The company boosted full-year adjusted EPS guidance to $0.15 to $0.25 from the previous forecast of $0.10 to $0.20. It affirmed the revenue outlook of $2.7 billion to $2.75 billion.Analysts expect EPS of $0.15 on revenue of $2.71 billion.KinderCare shares fell 6.2% in after-hours trading.

$KLC